Competition and Optimism: GSK's CEO Walmsley Foresees Growth Despite Competition In RSV Vaccine Market
Published
Emma Walmsley, the Chief Executive Officer of GSK plc GSK, expressed confidence in its respiratory syncytial virus (RSV) vaccine, Arexvy, anticipating sales to surpass £1 billion ($1.26 billion) in its debut year. This positive outlook follows an impressive start in the U.S. market for Arexvy,…
#emmawalmsley #gskplc #gsk #rsv #arexvy #reutersnewsmaker #fda #pfizerinc #zantac